Status:
COMPLETED
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
Lead Sponsor:
Dr. Falk Pharma GmbH
Conditions:
Lymphocytic Colitis
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.
Eligibility Criteria
Inclusion
- Signed informed consent
- Symptoms and signs of indication of lymphocytic colitis
Exclusion
- Infectious diarrhoea,
- Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract or endoscopic-histological findings Celiac disease
- Pregnancy or breast-feeding,
- Participation in an other clinical trial
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT01209208
Start Date
May 1 2010
End Date
June 1 2017
Last Update
July 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf
Hamburg, Germany